Bill & Melinda Gates Foundation Trust
Guided by the belief that every life has equal value, the Bill & Melinda Gates Foundation works to help all people lead healthy, productive lives. In developing countries, it focuses on improving people's health and giving them the chance to lift themselves out of hunger and extreme poverty. In the United States, it seeks to ensure that all people - especially those with the fewest resources - have access to the opportunities they need to succeed in school and life. Based in Seattle, Washington, the foundation is led by CEO Jeff Raikes and Co-chair William H. Gates Sr., under the direction of Bill and Melinda Gates and Warren Buffett.
-
Novavax (NVAX) Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
-
Novavax (NVAX), SK bioscience Announce Collaboration for Novavax' COVID-19 Vaccine Candidate
-
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
-
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
-
Exclusive: Vaccine alliance finds manufacturing capacity for 4 billion doses of coronavirus vaccines
-
Pre-Open Movers 03/12: (CEMI) (INO) (APT) Higher; (ZAGG) (NCLH) (CCL) Lower (more...)
-
Novavax (NVAX) Highlights New Data from Novavax Phase 3 Prepare Trial of ResVax at 2019 IDSOG Meetings
-
Novavax (NVAX) Provides Updates on Global Pathways to Licensure for ResVax
-
Novavax (NVAX) to Present RSV Maternal Immunization Program Phase 3 Data and Participate in Panel on COPD
-
Novavax (NVAX) Phase 3 Prepare Trial of ResVax for Prevention of RSV Disease in Infants Doesn't Meet Primary Endpoint
-
Novavax to Present Clinical Data on RSV F and NanoFlu(TM) Vaccines at World Vaccine Congress
-
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
-
Novavax to Present Clinical Data on RSV F and NanoFlu™ Vaccines at World Vaccine Congress
-
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
-
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
-
Novavax Provides Corporate Update and Report of Fourth Quarter and Year-End 2017 Financial Results
-
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu(TM) Vaccine
-
Novavax (NVAX) Says Phase 3 Trial of RSV F Vaccine for Infants via Maternal Immunization Will Continue; Provides Update on Phase 1/2 Trial of NanoFlu Vaccine
-
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
-
Novavax Continues Phase 3 Trial of the RSV F Vaccine for Infants via Maternal Immunization and Provides Update on Phase 1/2 Trial of the NanoFlu™ Vaccine
-
Novavax Reports Third Quarter 2017 Financial Results
-
Novavax Reports Second Quarter 2017 Financial Results
-
Novavax (NVAX) Reports Topline Data from Phase 2 Older Adult Trial for RSV F Vaccine Programs; Offers Update on Path Forward
-
Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs
-
Novavax (NVAX) Tops Q3 EPS by 2c; Will Implement Restructuring Plan
-
Novavax (NVAX) Commences Enrollment in RSV F Vaccine Phase 3
-
Novavax (NVAX) Announces Positive Top-Line Data from RSV F Vaccine Phase 2 in Infants
-
Novavax (NVAX) Announces Receipt of Grant from Bill & Melinda Gates Foundation for RSV F Vaccine Phase 3